PWWP2A Activators
PWWP2A is deeply involved in the interpretation of epigenetic information and the subsequent regulation of gene expression. Compounds that modulate the chromatin state can have profound effects on PWWP2A's functional activity. For instance, certain inhibitors that lead to the hypomethylation of DNA create an altered epigenetic landscape, which allows PWWP2A to bind chromatin with modified affinity, thus changing its regulatory impact on gene expression. Similarly, the inhibition of specific histone deacetylases can result in hyperacetylation of histones. This change in the chromatin structure may allow PWWP2A to interact more effectively with histone marks, enhancing its ability to influence transcriptional outcomes. Furthermore, agents that raise the levels of second messengers such as cAMP within the cell can activate protein kinases, which in turn can modify transcription factors and chromatin-associated proteins that PWWP2A may interact with, thereby indirectly increasing PWWP2A activity by creating a favorable context for its action.
In addition to influencing the epigenetic context, other compounds can impact PWWP2A activity by affecting signaling pathways and cellular processes that indirectly govern its role. For example, agents that inhibit kinases involved in cell cycle progression can alter chromatin dynamics, potentially facilitating PWWP2A's ability to act during key stages of cell division. Moreover, an increase in intracellular calcium levels can trigger a cascade of events activating calcium-dependent kinases that may modify proteins interacting with PWWP2A, thereby impacting its chromatin-associated functions. Similarly, specific kinase inhibitors that disrupt major signaling pathways like the MAPK/ERK cascade can lead to changes in the activity of transcription factors and the chromatin state, which could indirectly enhance PWWP2A's regulatory functions.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Directly activates protein kinase C (PKC). PKC activation can lead to phosphorylation of transcription factors and histones, potentially influencing chromatin structure and gene expression where PWWP2A may be involved in interpreting epigenetic marks. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Selective calcium ionophore, raising intracellular Ca2+ levels. Increased Ca2+ can activate calcium-dependent protein kinases which may alter chromatin compaction, thereby potentially influencing PWWP2A's role in chromatin-mediated transcriptional regulation. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
DNA methyltransferase inhibitor that leads to hypomethylation of DNA. It may indirectly activate PWWP2A by altering the epigenetic landscape, thus affecting PWWP2A's ability to bind methylated chromatin and regulate gene expression. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Histone deacetylase inhibitor that causes hyperacetylation of histones, potentially modifying chromatin structure in a way that allows PWWP2A to more effectively participate in the regulation of gene expression through its interaction with histone marks. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
cAMP analog that activates cAMP-dependent pathways, potentially enhancing PWWP2A-mediated transcriptional regulation by modulating the phosphorylation status of associated transcription factors or other chromatin-associated proteins. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
Aurora kinase inhibitor that may stabilize the chromatin structure, thereby potentially affecting PWWP2A’s ability to interact with chromatin and exert its effects on gene expression. | ||||||
BI 2536 | 755038-02-9 | sc-364431 sc-364431A | 5 mg 50 mg | $151.00 $525.00 | 8 | |
Polo-like kinase 1 (Plk1) inhibitor that may influence mitotic progression and chromatin dynamics, potentially facilitating PWWP2A's role in gene regulation during cell division. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
MEK inhibitor that disrupts the MAPK/ERK pathway, potentially leading to altered transcription factor activity and chromatin state, which could enable PWWP2A to more effectively bind to its targets and regulate gene expression. | ||||||
SGC-CBP30 | 1613695-14-9 | sc-473871 sc-473871A | 5 mg 10 mg | $178.00 $338.00 | ||
Bromodomain and extraterminal domain (BET) protein inhibitor that may modify chromatin accessibility and influence gene expression patterns, potentially affecting PWWP2A's interaction with chromatin and its role in transcriptional regulation. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
BET inhibitor that may alter chromatin state, thereby potentially enhancing PWWP2A's ability to regulate gene expression through its interaction with modified histones or other chromatin-associated factors. | ||||||